| Similar Articles |
|---|
 |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Pathways Promise By using the right tools, even a modest genomic data set can generate a good view into a particular biological pathway. Now, a range of new technologies is arising from academia as well as the commercial sector to meet this need.   |
Pharmaceutical Executive
February 1, 2011
Jill Wechsler |
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome? |
Bio-IT World
September 2006
Kevin Davies |
The $2 Billion Pill? Challenges and opportunities facing the drug industry were recurring themes in the quartet of keynote speeches at the 2006 Drug Discovery Technology conference. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Fast Company
November 2010
Elizabeth Svoboda |
The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs. |
Pharmaceutical Executive
September 1, 2012
Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
Bio-IT World
December 10, 2002
Arielle Emmett |
Locus Focus Cheminformatics company Locus Discovery is a technology darling and an entrepreneur's dream, but it faces a dilemma over how much of its proprietary drug discovery software and data to reveal. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Bio-IT World
November 2006
John Russell |
Pathway Pioneers Innovative uses for pathway tools and exciting results from early users are sprouting like mushrooms after a spring rain -- albeit following a few harsh winters. And the usually risk-averse pharmaceutical industry has led in adopting pathway tools. |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Bio-IT World
September 16, 2004
Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open |
Bio-IT World
January 21, 2005
Jim Golden |
Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year. |
Bio-IT World
July 15, 2003 |
Millennium's PARIS Illuminates Pathways To address high-throughput-data challenges, Millennium Pharmaceuticals built the PAthway Resource and Information System, or PARIS -- a unique platform for combining knowledge from heterogeneous data sources in the construction of a pathway knowledgebase. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
Bio-IT World
October 14, 2004
Zachary Zimmerman |
Follow the Pathway to Increased ROI Although this software has been commercially available for only a year, Ingenuity claims nine of the top 10 pharmaceutical companies as customers, including Pfizer, Wyeth, GlaxoSmithKline, and Aventis. |
Pharmaceutical Executive
January 1, 2012
Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
Bio-IT World
February 2006
John Russell |
Preventable Vioxx Problems? Pathway analysis tools might have identified Vioxx's problematic off-target activity much earlier. Wondering which modeling approach to use for your project? |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Pharmaceutical Executive
September 1, 2011
Jill B. Conner |
Complex Biologics: The View from Teva Industry and regulators alike must grapple with the sensitivities associated with developing bio-similar drugs. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Bio-IT World
Dec 2005/Jan 2006
John Russell |
GeneGo's Pathway to Profits Steady growth in literature citations plus several major pharmaceutical deals and now a recent FDA commitment suggest pathway technology is gaining sufficient credibility and the furthest along commercially of all the systems biology niches. |
